Irbesartan + Hidroclorotiazida Generis Phar

Irbesartan and Hydrochlorothiazide, the active ingredients in Irbesartan + Hidroclorotiazida Generis Phar, are an angiotensin II receptor blocker and a thiazide diuretic presented as an oral tablet for oral use. They are used to lower high blood pressure in adult patients and are indicated for the management of hypertension in patients who require combination therapy.

GNH USA supplies Irbesartan + Hidroclorotiazida Generis Phar as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide through regulated supply chains.

Irbesartan/Hydrochlorothiazide is indicated for the management of hypertension, a condition characterized by elevated arterial pressure. - Hypertension: lowers systolic and diastolic blood pressure, helping to reduce cardiovascular risk. - Essential hypertension: provides effective blood pressure control when monotherapy is insufficient. - Hypertension requiring combination therapy: combines an ARB with a thiazide diuretic to achieve target pressures in patients needing multiple mechanisms. - Renal hypertension: assists in blood pressure reduction in patients with mild renal impairment.

The combination may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Dizziness or light‑headedness - Headache - Fatigue or weakness - Increased urination - Electrolyte disturbances (e.g., low potassium) - Mild gastrointestinal discomfort

Serious or Rare Side Effects: - Severe allergic reactions such as angioedema - Acute kidney injury - Significant drops in blood pressure (hypotension) - Elevated blood urea nitrogen or creatinine - Pancreatitis - Severe skin reactions (e.g., Stevens‑Johnson syndrome)

When prescribing Irbesartan/HCTZ, clinicians should observe several precautionary measures. - Monitor blood pressure: ensure adequate control and avoid hypotension. - Assess renal function: check serum creatinine and eGFR before and during therapy. - Check electrolytes: especially potassium and sodium levels. - Avoid use in pregnancy: drug is classified as pregnancy category D. - Use caution in elderly patients: increased sensitivity to blood pressure changes. - Store at room temperature: keep in the original container, protect from moisture and light.

Irbesartan/HCTZ can interact with other medicines, affecting efficacy or safety.

Major Interactions (Avoid): - Concomitant use with ACE inhibitors or aliskiren in diabetic patients: risk of hyperkalemia and renal impairment. - Potassium‑sparing diuretics or supplements: may cause dangerous hyperkalemia. - Lithium: increased lithium levels leading to toxicity. - NSAIDs (e.g., ibuprofen, naproxen): may reduce antihypertensive effect and impair renal function.

Moderate Interactions (Monitor Closely): - Other antihypertensives (beta‑blockers, calcium channel blockers): may enhance blood pressure lowering, requiring dose adjustment. - CYP2C9 inhibitors (e.g., fluconazole, amiodarone): can increase irbesartan plasma concentrations. - Thiazide‑type diuretics: additive electrolyte disturbances. - Antidiabetic agents: may require monitoring of blood glucose as blood pressure changes can affect glucose control.